I second tada's sentiment that Friday morning can't get here soon enough. 

We know we're getting data this is positive....but beauty is in the eye of the beholder.  Biogen has presented what that company believes to be postive news, but the market is less certain.  Given that BETonMACE cognition data is from a subgroup I don't think the bar will be as high for Apabetalone at this stage....right now we just need positive indications that can get the market excited about a more specific trial, then the microscope will come out on the numbers.